Literature DB >> 19080776

[Stapedotomy outcomes in the treatment of otosclerosis: our experience].

Jorge L Merán Gil1, Elisabeth Masgoret Palau, Francisco J Avilés Jurado, Esther Domènech Vadillo, Juan C Flores Martín, Enric Figuerola Massana.   

Abstract

OBJECTIVE: The main objective of our study is to identify whether there is measurable audiometric deterioration in patients undergoing stapedotomy with a follow-up of more than eight years. MATERIAL AND
METHOD: We conducted a retrospective clinical study in which we reviewed a total of 150 case histories of patients with stapedotomy at our department between 1993 and 1997, with a successful initial audiological assessment using tone audiometry in the first three months after surgery and later audiometrical follow-up.
RESULTS: We obtained a significant mean post-operative hearing impairment of 1.02 dB per year, with a pre-operative mean PTA of 51.45 dB, going on to early post-operative mean PTA of 26.71 dB, and later post-operative mean PTA of 35.42 dB, with all these changes turning out to be statistically significant.
CONCLUSIONS: The auditory level obtained after surgery worsens as the years go by, but always without exceeding the hearing loss prior to surgery.

Entities:  

Mesh:

Year:  2008        PMID: 19080776

Source DB:  PubMed          Journal:  Acta Otorrinolaringol Esp        ISSN: 0001-6519


  3 in total

1.  Effectiveness of stapedotomy in improving hearing sensitivity for 53 otosclerotic patients: retrospective review.

Authors:  Farid Alzhrani; Mohammad M Mokhatrish; Murad O Al-Momani; Hassan Alshehri; Abdulrahman Hagr; Soha N Garadat
Journal:  Ann Saudi Med       Date:  2017 Jan-Feb       Impact factor: 1.526

2.  Hearing results in adults after stapedotomy.

Authors:  Emmanuel Sara Kolo; R Ramalingam
Journal:  Niger Med J       Date:  2013-07

3.  Long term outcome of otosclerosis surgery.

Authors:  Maria Teresa Bernardo; Joana Dias; Daniela Ribeiro; Diamantino Helena; Artur Condé
Journal:  Braz J Otorhinolaryngol       Date:  2012 Jul-Aug
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.